Download PDF
Clin Colon Rectal Surg 2011; 24(3): 129-134
DOI: 10.1055/s-0031-1285996
© Thieme Medical Publishers

Carcinoid and Other Neuroendocrine Tumors of the Colon and Rectum

John Carl Eggenberger1 , 2
  • 1Department of Surgery, St. Joseph Mercy Hospital, Ann Arbor, Michigan
  • 2Associates in General and Vascular Surgery, Ypsilanti, Michigan
Further Information

Publication History

Publication Date:
26 August 2011 (online)

    Permissions and Reprints

ABSTRACT

Neuroendocrine tumors (NETs) are found throughout the intestinal tract and arise from the Kulchitsky cells located in the crypts of Lieberkühn. They are classified by site of origin and by degree of differentiation, with well-differentiated lesions representing those tumors formerly referred to as carcinoid tumors. The focus of this review is NETs of the appendix, colon, and rectum. The clinical presentation of these tumors is dependent on the primary site and many are discovered incidentally, either during screening or during the investigation of nonspecific abdominal complaints. Treatment is primarily via surgical removal as the response to chemotherapy has been traditionally poor. A noted exception to this has been with treatment of the carcinoid syndrome, which occurs almost exclusively in patients with liver metastases and is due to the release of bioactive peptides and amines directly into the systemic circulation. The use of somatostatin congeners to block the release of these substances has greatly ameliorated the devastating symptoms of this condition. Postresection follow-up is advocated, but specific recommendations are lacking an evidentiary basis. NETS, particularly those of the small bowel, colon, and appendix, are seen in association with other synchronous or metachronous malignancies, often of the gastrointestinal tract. However, the utility of subsequent screening and surveillance is unproven.

KEYWORDS

NETs - carcinoid tumor - carcinoid syndrome - serotonin - somatostatin

REFERENCES

  • 1 Langhans T. Ueber einen drusenpolyp im ileum.  Virchows Arch Pathol Anat Physiol Klin Med. 1867;  38 559-560
    PubMedGoogle Scholar
  • 2 Lubarsch O. Uber den primaren Krebs des ileum nebst Bemerkungen uber das gleichzeitige Vorkommen von Krebs und Tuberkulose.  Virchows Arch. 1888;  3 280-317
    PubMedGoogle Scholar
  • 3 Oberndorfer S. Karzenoide tumoren des dunndarms.  Franfurt Z Pathol. 1907;  1 426-430
    PubMedGoogle Scholar
  • 4 Gosset A, Masson P. Tumeurs endocrines de l'appendice.  Presse Med. 1914;  25 237-239
    PubMedGoogle Scholar
  • 5 Williams E D, Sandler M. The classification of carcinoid tumours.  Lancet. 1963;  1 (7275) 238-239
    PubMedGoogle Scholar
  • 6 Solcia E, Kloppel G, Sobin L H et al.. Histological Typing of Endocrine Tumours. WHO International Histological Classification of Tumours. 2nd ed. Berlin: Springer; 2000
    Google Scholar
  • 7 Delcore R, Friesen S R. Gastrointestinal neuroendocrine tumors.  J Am Coll Surg. 1994;  178 (2) 187-211
    PubMedGoogle Scholar
  • 8 Crocetti E, Paci E. Malignant carcinoids in the USA, SEER 1992-1999. An epidemiological study with 6830 cases.  Eur J Cancer Prev. 2003;  12 (3) 191-194
    CrossrefPubMedGoogle Scholar
  • 9 Kulke M H, Mayer R J. Carcinoid tumors.  N Engl J Med. 1999;  340 (11) 858-868
    CrossrefPubMedGoogle Scholar
  • 10 Shields C J, Tiret E, Winter D C. International Rectal Carcinoid Study Group . Carcinoid tumors of the rectum: a multi-institutional international collaboration.  Ann Surg. 2010;  252 (5) 750-755
    CrossrefPubMedGoogle Scholar
  • 11 Yoon S N, Yu C S, Shin U S, Kim C W, Lim S B, Kim J C. Clinicopathological characteristics of rectal carcinoids.  Int J Colorectal Dis. 2010;  25 (9) 1087-1092
    CrossrefPubMedGoogle Scholar
  • 12 Kwaan M R, Goldberg J E, Bleday R. Rectal carcinoid tumors: review of results after endoscopic and surgical therapy.  Arch Surg. 2008;  143 (5) 471-475
    CrossrefPubMedGoogle Scholar
  • 13 Boudreaux J P, Klimstra D S, Hassan M M North American Neuroendocrine Tumor Society (NANETS) et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum.  Pancreas. 2010;  39 (6) 753-766
    CrossrefPubMedGoogle Scholar
  • 14 Anthony L B, Strosberg J R, Klimstra D S North American Neuroendocrine Tumor Society (NANETS) et al. The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (NETS): well-differentiated NETS of the distal colon and rectum.  Pancreas. 2010;  39 (6) 767-774
    CrossrefPubMedGoogle Scholar
  • 15 Krenning E P, Kooij P PM, Bakker W H et al.. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history.  Ann N Y Acad Sci. 1994;  733 496-506
    CrossrefPubMedGoogle Scholar
  • 16 Honig L J, Weingarten G. A gastric carcinoid tumor with massive bleeding.  Am J Gastroenterol. 1974;  61 (1) 40-44
    PubMedGoogle Scholar
  • 17 Parris W C, Oates J A, Kambam J, Shmerling R, Sawyers J F. Pre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome.  Can J Anaesth. 1988;  35 (4) 413-416
    CrossrefPubMedGoogle Scholar
  • 18 Quinlivan J K, Roberts W A. Intraoperative octreotide for refractory carcinoid-induced bronchospasm.  Anesth Analg. 1994;  78 (2) 400-402
    CrossrefPubMedGoogle Scholar
  • 19 Claure R E, Drover D D, Haddow G R, Esquivel C O, Angst M S. Orthotopic liver transplantation for carcinoid tumour metastatic to the liver: anesthetic management.  Can J Anaesth. 2000;  47 (4) 334-337
    CrossrefPubMedGoogle Scholar
  • 20 Orbach-Zinger S, Lombroso R, Eidelman L A. Uneventful spinal anesthesia for a patient with carcinoid syndrome managed with long-acting octreotide.  Can J Anaesth. 2002;  49 (7) 678-681
    CrossrefPubMedGoogle Scholar
  • 21 Rinke A, Müller H H, Schade-Brittinger C PROMID Study Group et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.  J Clin Oncol. 2009;  27 (28) 4656-4663
    CrossrefPubMedGoogle Scholar
  • 22 Schnirer I I, Yao J C, Ajani J A. Carcinoid—a comprehensive review.  Acta Oncol. 2003;  42 (7) 672-692
    CrossrefPubMedGoogle Scholar
  • 23 Eriksson B K, Larsson E G, Skogseid B M, Löfberg A M, Lörelius L E, Oberg K E. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors.  Cancer. 1998;  83 (11) 2293-2301
    CrossrefPubMedGoogle Scholar
  • 24 Gupta S, Yao J C, Ahrar K et al.. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.  Cancer J. 2003;  9 (4) 261-267
    CrossrefPubMedGoogle Scholar
  • 25 Strosberg J R, Choi J, Cantor A B, Kvols L K. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.  Cancer Contr. 2006;  13 (1) 72-78
    PubMedGoogle Scholar
  • 26 Kennedy A S, Dezarn W A, McNeillie P et al.. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.  Am J Clin Oncol. 2008;  31 (3) 271-279
    CrossrefPubMedGoogle Scholar
  • 27 Kwekkeboom D J, de Herder W W, Kam B L et al.. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.  J Clin Oncol. 2008;  26 (13) 2124-2130
    CrossrefPubMedGoogle Scholar
  • 28 Modlin I M, Lye K D, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors.  Cancer. 2003;  97 (4) 934-959
    CrossrefPubMedGoogle Scholar

John Carl EggenbergerM.D. 

Associates in General and Vascular Surgery, Michigan Heart and Vascular Institute

5325 Elliott Dr., Ste. 104, Ypsilanti, MI 48197

Email: eggenbej@trinity-health.org

      >